Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Roland Batson who wrote (27267)	1/6/1999 6:52:00 PM
From: Machaon	Respond to of 32384

<< Targets must cease or at least be somewhat more accurate. >> That's very true, right now. A $30 12-month target is worthless if Panretin Gel or ONTAK is turned down. Are these two approvals already factored into Ligand's share price? Whatcha think? If we get both approvals, what would be the effect on LGND? OTOH, I would be very surprised to see any real movement in LGND until this news comes out. Also, another question: Ligand has been in Phase II testing of Targretin Capsules, for about two years, for diabetes, in Europe. They've got to have a wealth of info from these trials. Could they use the safety data and other related efficacies, from these European trials, for their Targretin Phase II breast cancer trials that started in November, 1998? Regards, Bob